Hepatitis B Therapeutics: Competitive Landscape

This reports provides a data-driven overview of the current and future competitive landscape in Hepatitis B Therapeutics .

The analyst epidemiologists estimate that there will be 21.91 million diagnosed prevalent cases of HBV in 2024, which is expected to increase to 22.43 million diagnosed prevalent cases by 2029.
The HBV treatment landscape has experienced successive waves of revolutionary change and is now dominated by antivirals and immunomodulatory therapies.
The HBV therapeutics pipeline holds 184 molecules, with one asset in the pre-registration stage, one asset in Phase III development, and 36 assets in Phase II development.
Over the past decade, 914 clinical trials have been conducted in HBV. The highest number of studies were initiated in 2018, with 118 trials, followed by 2020 with 107 trials.
Over the past decade, partnerships have been the most common type in North America and the APAC region. Meanwhile, licensing agreements led as the dominant deal in Europe, South and Central America, and Africa.

Scope

The Hepatitis B Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Hepatitis B Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Hepatitis B Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.